



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB00,814-A 400.034)

In the Application of:)
McSwiggen, et al.)

Serial No. 09/927,046)

Filed: August 9, 2001)

For: METHOD AND REAGENT FOR THE)
INHIBITION OF CALCIUM ACTIVATED)
CHLORIDE CHANNEL-1 (CLCA-1))

Commissioner for Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:
 - ☒ Information Disclosure Statement;
 - ☒ Copies of IDS Citations for S/N 09/927,046 (3 U.S. Patent Applications, 11 U.S. Patents, 31 Foreign Patents and 172 Other References);
 - ☒ Information Disclosure Statement (IDS) PTO-1449 Form; and
 - ☒ Return Receipt Postcard.
2. With respect to additional fees, no additional fee is required.
3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in a box addressed to Commissioner for Patents, Washington, D.C. 20231 on January 31, 2002.

Date: January 31, 2002

By: *Andrew W. Williams*

Andrew W. Williams
Reg. No. 48,644

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, Fl. 32
Chicago, IL 60606
Telephone: (312) 913-0001

GP
1046
RECEIVED
MAR 01 2002
APR 09 2002
TECH CENTER 1600/2900
TECH CENTER 1600/2900
PATENT
#5/266



#5/K.T.
4/26
F.D.S.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB00,814-A 400.034)

PATENT

TECH CENTER 1600/2900

APR 09 2002

RECEIVED

In the Application of:)
McSwiggen, et al.)

Serial No. 09/927,046)

Filed: August 9, 2001)

For: METHOD AND REAGENT FOR THE)
INHIBITION OF CALCIUM ACTIVATED)
CHLORIDE CHANNEL-1 (CLCA-1))

Examiner: TB

Art Unit: 1646

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to the duty of disclosure provided by 37 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of all references cited are also listed in the PTO-1449 form enclosed herewith. It is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation

is intended as to the relative importance of any portion of the references. This Statement is not a representation that the cited references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

CITED REFERENCES

U.S. PATENT APPLICATION DOCUMENTS


No.	Document Number	Filing Date	Name
1.	60/101,074	9/21/98	Hartmann, et al.
2.	60/082,404	4/20/98	Thompson et al.
3.	09/406,643	9/27/99	Warburg


U. S. PATENT DOCUMENTS

No.	Document Number	Name	Publication Date if Appropriate
4.	4,987,071	Cech et al.	1/22/91
5.	5,334,711	Sproat et al.	8/2/94
6.	5,525,468	McSwiggen	6/11/96
7.	5,624,803	Noonberg et al.	4/29/97
8.	5,627,053	Osman et al.	5/6/97
9.	5,631,359	Chowrira et al.	5/20/97
10.	5,633,133	Long et al.	5/27/97
11.	5,672,695	Eckstein et al.	9/30/97
12.	5,716,824	Beigelman et al.	2/10/98
13.	5,849,902	Arrow et al.	12/15/98
14.	6,001,311	Brennan	12/4/99

FOREIGN PATENT DOCUMENTS

No.	Document Number	Name	Date	Country
15.	0 360 257 A2	Hampel et al.	28.03.90	EO





RECEIVED

APR 09 2002

TECH CENTER 1600/2900

No.	Document Number	Name	Date	Country
16.	91/03162	Rossi et al.	21.03.91	WO/PCT
17.	92/07065	Eckstein et al.	30.04.92	WO/PCT
18.	93/15187	Usman et al.	05.08.93	WO/PCT
19.	93/23057	Thompson et al.	25.11.93	WP/PCT
20.	93/23569	Draper et al.	25.11.93	WO/PCT
21.	94/02595	Sullivan et al.	03.02.94	WO/PCT
22.	95/04818	Draper et al.	16.02.95	WO/PCT
23.	95/11304	Usman et al.	27.04.95	WO/PCT
24.	95/13380	Draper et al.	18.05.95	WO/PCT
25.	95/23225	Stinchcomb et al.	31.08.95	WO/PCT
26.	96/10390	Ansell et al.	11.04.96	WO/PCT
27.	96/10391	Choi et al.	11.04.96	WO/PCT
28.	96/10392	Holland et al.	11.04.96	WO/PCT
29.	96/18736	Beigelman et al.	20.06.96	WO/PCT
30.	96/22689	Pyle et al.	01.08.96	WO/PCT
31.	97/26270	Wincott et al.	24.07.97	WO/PCT
32.	97/35562	Illum et al.	02/10/97	WO/PCT
33.	98/13526	Woolf	02.04.98	WO/PCT
34.	98/28317	rpelsky et al.	02.07.98	WO/PCT
35.	98/43993	eaker	08.10.98	WO/PCT
36.	98/50530	Jarvis et al.	12.11.98	WO/PCT
37.	98/58058	Ludwig et al.	23.12.98	WO/PCT
38.	99/04819	Klimuk et al.	04.02.99	WO/PCT
39.	99/05094	Beigelman et al.	22.07.98	WO/PCT
40.	99/16871	Eckstein et al.	08.04.99	WO/PCT
41.	99/44620	Holroyd et al.	10/09/99	WO/PCT


APR 09 2002

TECH CENTER 1600/2900

No.	Document Number	Name	Date	Country
42.	99/54459	Thompson et al.	28.10.99	WO/PCT
43.	99/55857	Beigelman et al.	28.04.99	WO/PCT
44.	99/60010	Bennett et al.	25.11.99	WO/PCT
45.	99/60166	Bennett et al.	25/11/99	WO/PCT

OTHER DOCUMENTS

No.	
46.	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," <u>Science</u> 271:1410-1413 (1996)
47.	Akhtar and Juliano, "Cellular uptake and intracellular fate of antisense oligonucleotides," <u>Trends in Cell Biology</u> 2:139-144 (1992)
48.	Aldrian-Herrada et al., "A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a <i>retro-inverso</i> delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons," <u>Nucleic Acids Research</u> 26:4910-4916 (1998)
49.	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," <u>Biochemistry</u> 34:6504-6512 (1995)
50.	Beaudry et al., "Directed Evolution of an RNA Enzyme," <u>Science</u> 257:635-641 (1992)
51.	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <u>J. Biol. Chem.</u> 270:25702-25708 (1995)
52.	Bellon et al., "Amino-Linked Ribozymes: Post-Synthetic Conjugation of Half-Ribozymes," <u>Nucleosides & Nucleotides</u> 16:951-954 (1997)
53.	Bellon et al., "Post-synthetically Ligated Ribozymes: An Alternative Approach to Iterative Solid-Phase Synthesis," <u>Bioconjugate Chem.</u> 8:204-212 (1997)
54.	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," <u>EBMO J.</u> 12:2567-2574 (1993)
55.	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions," <u>Genes & Development</u> 6:129-134 (1992)
56.	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the <i>Tetrahymena</i> Ribozyme," <u>Biochemistry</u> 35:648-658 (1996)
57.	Boado, "Antisense drug delivery through the blood-brain barrier," <u>Advanced Drug Delivery Reviews</u> 15:73-107 (1995)
58.	Boado et al., "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <u>Journal of Pharmaceutical Sciences</u> 87:1308-1315 (1998)



RECEIVED

APR 09 2002

TECH CENTER 1600/2900

59.	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," <i>Nucleic Acids Research</i> 22:4681-4688 (1994)
60.	Breaker et al., "A DNA enzyme with Mg ²⁺ -dependent RNA phosphoesterase activity," <i>Chemistry & Biology</i> 2(10):655-660 (1995)
61.	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," <i>TIBTECH</i> 12:268-275 (1994)
62.	Breaker, "Are engineered proteins getting competition from RNA?" <i>Current Opinion in Biotechnology</i> 7:442-448 (1996)
63.	Brennan et al., "Two-Dimensional Parallel Array Technology as a New Approach to Automated Combinatorial Solid-Phase Organic Synthesis," <i>Biotechnology and Bioengineering (Combinatorial Chemistry)</i> 61:33-45 (1998)
64.	Burgin et al., "Chemically Modified Hammerhead Ribozymes with Improved Catalytic Rates," <i>Biochemistry</i> 35:14090-14097 (1996) (volume no mistakenly listed as 6)
65.	Burlina et al., "Chemical Engineering of Rnase Resistant and Catalytically Active Hammerhead Ribozymes," <i>Bioorganic & Medicinal Chemistry</i> 5:1999-2010 (1997)
66.	Caruthers et al., "Chemical Synthesis of Deoxyoligonucleotides and Deoxyoligonucleotide Analogs," <i>Methods in Enzymology</i> 211:3-19 (1992)
67.	Cech, "Ribozymes and Their Medical Implications," <i>JAMA</i> 260:3030-3034 (1988)
68.	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," <i>Nucleic Acids Research</i> 23(20):4092-4096 (1995)
69.	Chen et al., "Multitarget-Ribozyme Directed to Cleave at up to Nine Highly Conserved HIV-1 env RNA Regions Inhibits HIV-1 Replication-Potential Effectiveness Against Most Presently Sequenced HIV-1 Isolates," <i>Nucleic Acids Research</i> 20:4581-4589 (1992)
70.	Chowrira et al., "In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-Processing Ribozyme Cassettes," <i>J. Biol. Chem.</i> 269:25856-25864 (1994)
71.	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," <i>Nature</i> 354:320-322 (1991)
72.	Christoffersen and Marr, "Ribozymes as Human Therapeutic Agents," <i>J. Med. Chem.</i> 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
73.	Christofferson et al., "Application of computational technologies to ribozyme biotechnology products," <i>Journal of Molecular Structure (Theochem)</i> 311:273-284 (1994) (Christoffersen)
74.	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From <i>Neurospora</i> VS RNA," <i>Biochemistry</i> 32:2795-2799 (1993)
75.	Couture and Stinchcomb, "Anti-gene therapy: the use of ribozymes to inhibit gene function," <i>Trends In Genetics</i> 12:510-515 (1996)
76.	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," <i>Advances in Pharmacology</i> 40:1-49 (1997)
77.	Crooke, "Antisense Therapeutics," <i>Biotechnology and Genetic Engineering Reviews</i> 15:121-157 (1998)
78.	Cunningham et al., "Cloning of an Epithelial Chloride Channel from Bovine Traches," <i>J. Biol. Chem.</i> 270: 31016-31026 (1995).



RECEIVED


APR 09 2002

TECH CENTER 1600/2900

79.	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of <i>in Vitro</i> Reaction Rates and Products," <u>J. Mol. Biol.</u> 256:31-49 (1996)
80.	Dreyfus, "Restriction Ribozymes?" <u>Einstein Quarterly Journal of Biology and Medicine</u> 6:92-93 (1988)
81.	Dropulic et al., "Functional Characterization of a U5 Ribozyme: Intracellular Suppression of Human Immunodeficiency Virus Type I Expression," <u>Journal of Virology</u> 66:1432-1441 (1992)
82.	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," <u>Proc. Natl. Acad. Sci. USA</u> 89:504-508 (1992)
83.	Earnshaw et al., "Modified Oligoribonucleotides as Site-Specific Probes of RNA Structure and Function," <u>Biopolymers</u> 48:39-55 (1998)
84.	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," <u>Nature</u> 365:566-568 (1993)
85.	Eible et al., "Cloning and Characterization of Lung-Endothelial Cell Adhesion Molecule-1 Suggest It Is an Endothelial Chloride Channel," <u>J. Biol. Chem.</u> , 272: 27853-27861 (1997).
86.	Elroy-Stein and Moss, "Cytoplasmic Expression System Based on Constitutive Synthesis of Bacteriophage T7 RNA Polymerase in Mammalian Cells," <u>Proc. Natl. Acad. Sci. USA</u> 87:6743-6747 (1990)
87.	Emerich et al., "Biocompatibility of Poly (DL-Lactide-co-Glycolide) Microspheres Implanted Into the Brain," <u>Cell Transplantation</u> 8:47-58 (1999)
88.	Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," <u>Gene</u> 82:53-61 (1989)
89.	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," <u>Biochimica et Biophysica Acta</u> 1329:345-356 (1997)
90.	Forster and Altman, "External Guide Sequences for an RNA Enzyme," <u>Science</u> 249:783-786 (1990)
91.	Freier et al., "Improved free-energy parameters for predictions of RNA duplex stability," <u>Proc. Natl. Acad. Sci. USA</u> 83:9373-9377 (1986)
92.	Gao and Huang, "Cytoplasmic Expression of a Reporter Gene by Co-Delivery of T7 RNA Polymerase and T7 Promoter Sequence with Cationic Liposomes," <u>Nucleic Acids Research</u> 21:2867-2872 (1993)
93.	Good et al., "Expression of small, therapeutic RNAs in human nuclei," <u>Gene Therapy</u> 4:45-54 (1997)
94.	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," <u>Biochemistry</u> 34:4068-4076 (1995)
95.	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," <u>Chemistry & Biology</u> 2:761-770 (1995)
96.	Gruber et al., "Genomic Cloning, Molecular Characterization, and Functional Analysis of Human CLCA1, the First Human Member of the Family of Ca ²⁺ -Activated Cl ⁻ Channel Proteins," <u>Genomics</u> , 54, 200-214 (1998)

APR 09 2002

TECH CENTER 1600/2900



No.	
	Gruber et al., "The murine calcium-sensitive chloride channel (mCaCC) is widely expressed in secretory epithelia and in other select tissues," <u>Histochem. Cell Biol.</u> , 110, 43-49 (1998)
98.	Gruber et al., "Molecular Cloning and Transmembrane Structure of hCLCA2 from Human Lung, Trachea, and Mammary Gland," <u>Am. J. Physiol.</u> , 276: C1261-C1270 (1999)
99.	Gruber et al., "Tumorigenicity of Human Breast Cancer is Associated with Loss of the Ca ²⁺ -activated Chloride Channel CLCA2," <u>Cancer Res.</u> , 59: 5488-5491 (1999).
100.	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," <u>Cell</u> 35:849-857 (1983)
101.	Guo and Collins, "Efficient <i>trans</i> -cleavage of a stem-loop RNA substrate by a ribozyme derived from <i>Neurospora</i> VS RNA," <u>EMBO J.</u> 14:368-376 (1995)
102.	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," <u>Biochemistry</u> 28:4929-4933 (1989)
103.	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," <u>Nucleic Acids Research</u> 18:299-304 (1990)
104.	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," <u>RNA</u> 1:210-218 (1995)
105.	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," <u>The Journal of Pharmacology and Experimental Therapeutics</u> 285:920-928 (1998)
106.	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," <u>Gene</u> 82:43-52 (1989)
107.	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," <u>Nature</u> 334:585-591 (1988)
108.	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," <u>Biochemistry</u> 34:15813-15828 (1995)
109.	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," <u>Biochemistry</u> 29:10159-10171 (1990)
110.	Herschlag and Cech, "Catalysis of RNA Cleavage by the <i>Tetrahymena thermophila</i> Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," <u>Biochemistry</u> 29:10172-10180 (1990)
111.	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," <u>Biochemistry</u> 33:3374-3385 (1994)
112.	Hertel et al., "Numbering System for the Hammerhead," <u>Nucleic Acids Research</u> 20:3252 (1992)
113.	Hunziker et al., "Nucleic Acid Analogues: Synthesis and Properties, in Modern Synthetic Methods," <u>VCH</u> , 331-417 (1995)
114.	Ishiwata et al., "Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether," <u>Chem. Pharm. Bull.</u> 43:1005-1011 (1995) (mistakenly referred to as Ishiwataet)
115.	Izant and Weintraub, "Constitutive and Conditional Suppression of Exogenous and Endogeneous Genes by Anti-Sense RNA," <u>Science</u> 229:345-352 (1985)




RECEIVED

APR 09 2002

TECH CENTER 1600/2900

116.	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," <u>Proc. Natl. Acad. Sci. USA</u> 86:7706-7710 (1989)
117.	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," <u>Nucleic Acids Research</u> 17:1371-1377 (1989) (also referred to as Jefferies)
118.	Jolliet-Riant and Tillement, "Drug transfer across the blood-brain barrier and improvement of brain delivery," <u>Fundam. Clin. Pharmacol.</u> 13:16-26 (1999)
119.	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," <u>Genes & Development</u> 7:130-138 (1993)
120.	Joyce et al., "Amplification, mutation and selection of catalytic RNA," <u>Gene</u> 82:83-87 (1989)
121.	Joyce, "Directed Molecular Evolution," <u>Scientific American</u> 267:90-97 (1992)
122.	Karpeisky et al., "Highly Efficient Synthesis of 2'-O-Amino Nucleosides And Their Incorporation in Hammerhead Ribozymes," <u>Tetrahedron Letters</u> 39:1131-1134 (1998)
123.	Kashani-Sabet et al., "Reversal of the Malignant Phenotype by an Anti-ras Ribozyme," <u>Antisense Research & Development</u> 2:3-15 (1992)
124.	Kent et al., "Lung Disease in Mice with Cystic Fibrosis," <u>J. Clin. Invest.</u> , 100(12): 3060-3069 (1997).
125.	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of <i>Tetrahymena</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 84:8788-8792 (1987)
126.	Knitt et al., "pH Dependencies of the <i>Tetrahymena</i> Ribozyme Reveal an Unconventional Origin of an Apparent pK _a ," <u>Biochemistry</u> 35:1560-1570 (1996)
127.	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisited; the NIH rule", <u>Nucleic Acids Research</u> , 26(18):4116-4120 (1998).
128.	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," <u>Blood</u> 91:852-862 (1998)
129.	Kumar and Ellington, "Artificial evolution and natural ribozymes," <u>FASEB J.</u> 9:1183-1195 (1995)
130.	Lasic and Papahadjopoulos, "Liposomes Revisited," <u>Science</u> 267:1275-1276 (1995)
131.	L'Huillier et al., "Cytoplasmic Delivery of Ribozymes Leads to Efficient Reduction in α -Lactalbumin mRNA Levels in C1271 Mouse," <u>EMBO J.</u> 11:4411-4418 (1992)
132.	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," <u>Nucleic Acids Research</u> 24:835-842 (1996)
133.	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the <i>Tetrahymena</i> Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," <u>Biochemistry</u> 34:14394-14399 (1995)
134.	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," <u>Methods Enzymol.</u> 217:47-66 (1993)
135.	Limbach et al., "Summary: the modified nucleosides of RNA," <u>Nucleic Acids Research</u> 22(12):2183-2196 (1994)
136.	Lisacek et al., "Automatic Identification of Group I Intron Cores in Genomic DNA Sequences," <u>J. Mol. Biol.</u> 235:1206-1217 (1994)



RECEIVED

APR 09 2002

TECH CENTER 100/2000

No.	
	Liszewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 90:8000-8004 (1993)
138.	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," <u>J. Biol. Chem.</u> 270(42):24864-24870 (1995)
139.	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," <u>Proc. Natl. Acad. Sci. USA</u> 91:6977-6981 (1994)
140.	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," <u>Leukemia Research</u> 20:925-930 (1996)
141.	McGarry and Lindquist, "Inhibition of heat shock protein synthesis by heat-inducible antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> 83:399-403 (1986)
142.	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," <u>RNA</u> 2:395-403 (1996)
143.	Mesmaeker et al, "Novel Backbone Replacements for Oligonucleotides," <u>American Chemical Society</u> , pp. 24-39 (1994)
144.	Metzger and Nyce, "Molecular mechanisms in allergy and clinical immunology," <u>J. Allergy Clin. Immunol.</u> , 104(2, Pt. 1), 260-266 (1999)
145.	Michel and Westhof, "Slippery substrates," <u>Nat. Struct. Biol.</u> 1:5-7 (1994)
146.	Michel et al., "Structure and Activities of Group II Introns," <u>Annu. Rev. Biochem.</u> 64:435-461 (1995)
147.	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," <u>Biochemistry</u> 34:2965-2977 (1995)
148.	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase," <u>Methods Enzymol.</u> 180:51-62 (1989)
149.	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," <u>Proc. Natl. Acad. Sci. USA</u> 93:6780-6785 (1996)
150.	Moore and Sharp, "Site-Specific Modification of Pre-mRNA: The 2'-Hydroxyl Groups at the Splice Sites," <u>Science</u> 256:992-996 (1992)
151.	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," <u>Critical Reviews in Oncogenesis</u> 7:151-190 (1996)
152.	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," <u>Biochemistry</u> 33:1271-1277 (1994)
153.	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," <u>Ann. Rev. Biochem.</u> 44:273-293 (1975)
154.	Noonberg et al., <i>In vivo</i> generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation," <u>Nucleic Acids Research</u> 22(14):2830-2836 (1994)
155.	Ohkawa et al., "Activities of HIV-RNA Targeted Ribozymes Transcribed From a 'Shot-Gun' Type Ribozyme-trimming Plasmid," <u>Nucleic Acids Symp. Ser.</u> 27:15-16 (1992)
156.	Ojwang et al., "Inhibition of Human Immunodeficiency Virus Type 1 Expression by a Hairpin Ribozyme," <u>Proc. Natl. Acad. Sci. USA</u> 89:10802-10806 (1992)
157.	Orgel, "Selection <i>in vitro</i> ," <u>Proc. R. Soc. London B.</u> 205:435-442 (1979)




RECEIVED

APR 09 2002

TECH CENTER 1600/2900

No.	
158.	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," <u>Proc. Natl. Acad. Sci. USA</u> 92:12510-12514 (1995)
159.	Pardridge et al., "Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier <i>in vivo</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 92:5592-5596 (1995)
160.	Perreault et al., "Mixed Deoxyribo- and Ribo-Oligonucleotides with Catalytic Activity," <u>Nature</u> 344:565-567 (1990) (often mistakenly listed as Perrault)
161.	Perrotta and Been, "A pseudoknot-like structure required for efficeint self-cleavage of hepatitis delta virus RNA," <u>Nature</u> 350:434-436 (1991)
162.	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," <u>Biochemistry</u> 31:16-21 (1992)
163.	Pieken et al., "Kinetic Characterization of Ribonuclease-Resistant 2'-Modified Hammerhead Ribozymes," <u>Science</u> 253:314-317 (1991)
164.	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," <u>Nucleic Acids Research</u> 21:4253-4258 (1993)
165.	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," <u>Biochemistry</u> 33:2716-2725 (1994)
166.	Ran and Benos, "Immunopurification and Structural Analysis of a Putative Epithelial C1-Channel Protein Isolated from Bovine Trachea," <u>J. Biol. Chem.</u> 267: 3618-3625 (1992)
167.	Robertson et al., "Purification and Properties of a Specific <i>Escherichia coli</i> Riobnuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," <u>J. Biol. Chem.</u> 247:5243-5251 (1972)
168.	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," <u>Aids Research and Human Retroviruses</u> 8:183-189 (1992)
169.	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," <u>Proc. Natl. Acad. Sci. USA</u> 94:4262-4266 (1997)
170.	Sarver et al., "Ribozymes as Potential Anti-HIV-1 Therapeutic Agents" <u>Science</u> 247:1222-1225 (1990)
171.	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In <i>Neurospora</i> Mitochondria," <u>Cell</u> 61:685-696 (1990)
172.	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a <i>Neurospora</i> Mitochondrial Plasmid Transcript," <u>Proc. Natl. Acad. Sci. USA</u> 88:8826-8830 (1991)
173.	Scanlon et al., "Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis Enzymes and Metallothionein," <u>Proc. Natl. Acad. Sci. USA</u> 88:10591-10595 (1991)
174.	Scaringe et al., "Chemical synthesis of biologically active oligoribonucleotides using β -cyanoethyl protected ribonucleoside phosphoramidites," <u>Nucl Acids Res.</u> 18:5433-5441 (1990)
175.	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," <u>The Journal of Biological Chemistry</u> 274:21783-21789 (1999)
176.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <u>Nucleic Acids Research</u> 24:573-581 (1996)
177.	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," <u>Cell</u> 81:991-1002 (1995)



RECEIVED

APR 09 2002

TECH CENTER 1600/2000


No.	
178.	Shabarova et al., "Chemical ligation of DNA: The first non-enzymatic assembly of a biologically active gene," <u>Nucleic Acids Research</u> 19:4247-4251 (1991)
179.	Shapiro, "Animal Models for Chronic Obstructive Pulmonary Disease; Age of Klotho and Marlboro Mice," <u>Am. J. Respir. Cell Mol. Biol.</u> , 22(1): 4-7 (2000).
180.	Stein, "Does antisense exist," <u>Nature Medicine</u> 1(11):1119-1121 (1995)
181.	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" <u>Science</u> 261:1004-1288 (1993)
182.	Strobel et al., "Exocyclic Amine of the Conserved G-U Pair at the Cleavage Site of the <i>Tetrahymena</i> Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," <u>Biochemistry</u> 35:1201-1211 (1996)
183.	Strobel et al., "Minor Groove Recognition of the Conserved G-U Pair at the <i>Tetrahymena</i> Ribozyme Reaction Site," <u>Science</u> 267:675-679 (1995)
184.	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," <u>Nature</u> 371:619-622 (1994)
185.	Sullenger and Cech, "Tethering Ribozymes to a Retroviral Packaging Signal for Destruction of Viral RNA," <u>Science</u> 262:1566-1569 (1993)
186.	Szostak, "In Vitro Genes," <u>TIBS</u> 17:89-93 (1993)
187.	Taira et al., "Construction of a novel RNA-transcript-trimming plasmid which can be used both <i>in vitro</i> in place of run-off and (G)-free transcriptions and <i>in vivo</i> as multi-sequences transcription vectors," <u>Nucleic Acids Research</u> 19:5125-5130 (1991)
188.	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," <u>RNA</u> 3:914-925 (1997)
189.	Thompson et al., "Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter," <u>Nucleic Acids Research</u> 23:2259-2268 (1995)
190.	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," <u>Proc. Natl. Acad. Sci. USA</u> 90:1300-1304 (1993)
191.	Turner et al., "Free Energy Increments for Hydrogen Bonds in Nucleic Acid Base Pairs," <u>J. Am. Chem. Soc.</u> 109:3783-3785 (1987)
192.	Tyler et al., "Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression," <u>Proc. Natl. Acad. Sci. USA</u> 96:7053-7058 (1999)
193.	Tyler et al., "Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo," <u>FEBS Letters</u> 421:280-284 (1998)
194.	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," <u>Nature</u> 328:596-600 (1987) (this is listed as Nature 327 in the various specifications, but it is actually 328)
195.	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," <u>Chemical Reviews</u> 90:544-584 (1990)
196.	Usman and Cedergren, "Exploiting the chemical synthesis of RNA," <u>TIBS</u> 17:334-339 (1992)
197.	Usman and McSwiggen, "Ch. 30 - Catalytic RNA (Ribozymes) as Drugs," <u>Annual Reports in Medicinal Chemistry</u> 30:285-294 (1995)



APR 09 2002

TECH CENTER 1600/2900

No.	
198.	Usman et al., "Automated Chemical Synthesis of Long Oligoribonucleotides Using 2'-O-Silylated Ribonucleoside 3'-O-Phosphoramidites on a Controlled-Pore Glass Support: Synthesis of a 43-Nucleotide Sequence Similar to the 3'-Half Molecule of an <i>Escherichia coli</i> Formylmethoionine tRNA," <u>J. Am. Chem. Soc.</u> 109:7845-7854 (1987)
199.	Usman et al., "Chemical modification of hammerhead ribozymes: activity and nuclease resistance," <u>Nucleic Acids Symposium Series</u> 31:163-164 (1994)
200.	Usman et al., "Hammerhead ribozyme engineering," <u>Current Opinion in Structural Biology</u> 1:527-533(1996)
201.	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by <i>in Vitro</i> Selection," <u>Biochemistry</u> 36:6495-6501 (1997)
202.	Van Doorninck et al., "A mouse model for the cystic fibrosis $\Delta F508$ mutation," <u>EMBO J.</u> , 14(18), 4403-11 (1995)
203.	Vassar et al., " β -Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE," <u>Science</u> 286:735-741 (1999)
204.	Ventura et al., "Activation of HIV-Specific Ribozyme Activity by Self-Cleavage," <u>Nucleic Acids Research</u> 21:3249-3255 (1993)
205.	Verma and Eckstein, "Modified Oligonucleotides: Synthesis and Strategy for Users," <u>Annu. Rev. Biochem.</u> 67:99-134 (1998)
206.	Vyle et al., "Sequence- and Strand-Specific Cleavage in Oligodeoxyribonucleotides and DNA Containing 3'-Thiothymidine," <u>Biochemistry</u> 31:3012-3018 (1992)
207.	Wincott et al., "Synthesis, deprotection, analysis and purification of RNA and ribozymes," <u>Nucleic Acids Research</u> 23(14):2677-2684 (1995)
208.	Wincott et al., "A Practical Method for the Production of RNA and Ribozymes," <u>Methods in Molecular Biology</u> 74:59-69 (1997)
209.	Wu-Pong, "Oligonucleotides: Opportunities for Drug Therapy and Research," <u>Biopharm</u> , November 1994.
210.	Yu et al., "A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1," <u>Proc. Natl. Acad. Sci. USA</u> 90:6340-6344 (1993)
211.	Yuan et al., "Targeted cleavage of mRNA by human RNase P," <u>Proc. Natl. Acad. Sci. USA</u> 89:8006-8010 (1992)
212.	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the <i>Tetrahymena</i> ribozyme," <u>Nucleic Acids Research</u> 24:854-858 (1996)
213.	Zaug et al., "The <i>Tetrahymena</i> Ribozyme Acts Like an RNA Restriction Endonuclease," <u>Nature</u> 324:429-433 (1986)
214.	Zeihner et al., "A Mouse Model for the $\Delta F508$ Allele of Cystic Fibrosis," 1995, <u>J. Clin Invest.</u> , 96(4), 2051-64
215.	Zhou et al., "Synthesis of Functional mRNA in Mammalian Cells by Bacteriophage T3 RNA Polymerase," <u>Mol. Cell. Biol.</u> 10:4529-4537 (1990)
216.	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," <u>Cell</u> 83:529-538 (1995)
217.	Zhu et al., Blocking of Lung Endothelial Cell Adhesion Molecule-1 (Lu-ECAM-1) Inhibits Murine Melanoma Lung Metastasis, 1992, <u>J. Clin Invest.</u> , 89, 1718-1724




in accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Date: January 31, 2002

By: 
Andrew W. Williams
Registration No. 48,644